Author:
Kovaleva Olga V.,Podlesnaya Polina A.,Chang Viktor L.,Ognerubov Nikolai A.,Gratchev Alexei N.,Kozlov N. A.,Stilidi Ivan S.,Kushlinskii Nikolai E.
Abstract
A comprehensive analysis of the cell phenotype of the inflammatory infiltrate of the tumor stroma represents a promising area of molecular oncology. The study of not only soluble forms of various immunoregulatory molecules, but also their membrane-bound forms is also considered highly relevant. We performed a comprehensive analysis of tissue and circulating forms of the PD-1 and PD-L1 proteins, as well as macrophage and B-cell markers in the tumor stroma of gastric cancer, to assess their clinical and prognostic significance. The tumor and blood plasma samples from 63 gastric cancer patients were studied using ELISA and immunohistochemistry. Malignant gastric tumors were shown to be strongly infiltrated by B-cells, and their number was comparable to that of macrophages. For PU.1 expression, an association with tumor size was observed; i.e., larger tumors were characterized by fewer PU.1+ infiltrating cells (p = 0.005). No clinical significance was found for CD20 and CD163, but their numbers were higher at earlier stages of the disease and in the absence of metastases. It was also demonstrated that the PD-L1 content in tumor cells was not associated with the clinical and morphological characteristics of GC. At the same time, PD-L1 expression in tumor stromal cells was associated with the presence of distant metastases. The analysis of the prognostic significance of all the markers studied demonstrated that CD163 was statistically significantly associated with a poor prognosis for the disease (p = 0.019). In addition, PD-L1 expression in tumor cells tended to indicate a favorable prognosis (p = 0.122). The results obtained in this work indicate that the study of soluble and tissue markers of tumor stroma is promising in prognosticating the course of GC. The search for combinations of markers seems to be highly promising, with their comprehensive analysis capable of helping personalize advanced antitumor therapy.
Reference33 articles.
1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. // CA Cancer J. Clin. 2018. V. 68. № 6. P. 394–424.
2. Gonzalez C.A., Sala N., Rokkas T. // Helicobacter. 2013. V. 18 Suppl 1. P. 34–38.
3. Nomura A., Grove J.S., Stemmermann G.N., Severson R.K. // Cancer Res. 1990. V. 50. № 21. P. 7084.
4. Brooks-Wilson A.R., Kaurah P., Suriano G., Leach S., Senz J., Grehan N., Butterfield Y.S., Jeyes J., Schinas J., Bacani J., et al. // J. Med. Genet. 2004. V. 41. № 7. P. 508–517.
5. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R., et al. // N. Engl. J. Med. 2008. V. 358. № 1. P. 36–46.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献